Article

FDA Approves Tazarotene Lotion, 0.045%, for Acne Vulgaris

Tazarotene is the first acne treatment to be available in a lotion form, showing strong efficacy with favorable tolerability.

The FDA has approved the new drug application for Ortho Dermatologics’ tazarotene (Arazlo) lotion, 0.045%, for the topical treatment of acne vulgaris in patients age 9 years and older. Tazarotene is the first acne treatment to be available in a lotion form, showing strong efficacy with favorable tolerability, according to the company.

The approval comes from results of 2 different phase 3 randomized, double-blind clinical trials that included 1614 patients with moderate to severe acne. All primary endpoints were met with statistical significance, showing tazarotene lotion to be generally well-tolerated in the clinical study population.

In addition, a phase 2 head-to-head study between 2 tazarotene creams, 0.1% and 0.045%, showed the latter had similar treatment success rates, and similar reductions in both inflammatory and noninflammatory lesions over 12 weeks.

Common adverse effects of tazarotene lotion, 0.045%, include skin dryness, pain, redness, excessive flaking, or peeling.

REFERENCE

FDA approves Ortho Dermatologics’ Arazlo (tazarotene) lotion, 0.045%, for acne vulgaris [news release]. Bridgewater, NJ; Bausch Health: December 19, 2019. https://ir.bauschhealth.com/news-releases/2019/12-19-2019-115754291. Accessed December 20, 2019.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com